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Cardiovascular disease (CVD) remains the leading cause of death globally and its 
prevention is still suboptimal. Cardiovascular risk assessment is a fundamental component 
of CVD prevention – the common approach involves identifying individuals at high CVD risk 
and targeting them for lifestyle and pharmacological interventions. Guidelines by the 
American College of Cardiology/American Heart Association (ACC/AHA) task force1 and the 
European Society of Cardiology (ESC)2 are the major CVD prevention guidelines that are 
influencing clinical practice. These guideline bodies recommend the Pooled Cohort 
equations and the Systematic Coronary Risk Evaluation (SCORE)3, 4 algorithm respectively 
for 10-year CVD risk estimation. Other well-known CVD risk algorithms include the 
Framingham Risk Score (FRS)5 and the Reynolds Risk Score (RRS).6, 7 The performance of 
a risk prediction score is assessed using measures which include calibration and 
discrimination.8  Calibration as measured by the goodness-of-fit statistic, is the ability to 
correctly estimate the risk of a future event. Discrimination is the ability of the risk score to 
separate individuals at higher risk from those at lower risk and it is assessed using the area 
under the receiver-operating characteristic (ROC) curve or C statistic (Harrell’s C-index9).8   
 
The Pooled Cohort equations employed by ACC/AHA guidelines are based on any 
atherosclerotic CVD (ASCVD) events;1 whereas SCORE is based on fatal CVD outcomes.3, 4 
In addition, different risk thresholds are recommended for statin treatment initiation in 
primary CVD prevention. The ACC/AHA has lowered the threshold for statin initiation to a 
7.5% 10-year risk of ASCVD;1 in contrast, the ESC has preserved the 5% 10-year risk for 
fatal ASCVD estimated by SCORE.10 Reports from previous studies have indicated varying 
performances of these scores in different populations.11-13 The ACC/AHA risk calculator has 
been suggested to overestimate CVD risk.11 The SCORE model with a restricted age range 
(40-65 years) has focused on fatal ASCVD thereby disregarding nonfatal events.3 Due to the 
varying risk for fatal ASCVD across Europe, two standard versions of SCORE models were 
recommended by the 2003 ESC guidelines10 – low and high risk SCORE versions for low 
and high CVD mortality countries respectively. Given the declining rates of fatal ASCVD 
across most of Europe, it appears many European countries are using miscalibrated SCORE 
models.14 Therefore, there have been calls to re-calibrate SCORE to target populations, as 
risk models perform best when used in the population from which it was developed.14 Risk 
scores need to be well calibrated to the target population when decisions regarding 
treatment initiation are based on absolute risk. To generate more accurate CVD risk 
prediction for a particular population, risk models need to be re-calibrated.  
There is paucity of large-scale studies that have provided head-to-head comparisons of 
standard risk prediction algorithms.  
To address how four widely-used risk prediction algorithms (PCE, SCORE, FRS, and RRS) 
differ in their predictive accuracy and clinical performance, Di Angelantonio and colleagues 
compared original and re-calibrated versions of these algorithms across multiple settings in 
an elegant analysis.15 The authors employed data on over 350,000 people (aged 40-79 
years) without known CVD at baseline using comprehensive statistical analyses on risk 
scores re-calibration based on 86 prospective cohorts. For each participant, they 
implemented original versions of FRS, SCORE, PCE and RRS to calculate the predicted 10-
year CVD risk. These scores were then re-calibrated using the risk factor profile and CVD 
incidence of the target populations.  
 
The four evaluated risk scores vary in their risk factors and CVD endpoints (Table). The use 
of uniform criteria for outcomes needs serious consideration when evaluating the value of 
risk scores. CHD outcomes manifest in various ways such as sudden cardiac death, acute 
coronary syndromes, myocardial infarction (MI), and diagnosed using different non-invasive 
exercise testing and imaging techniques, such as coronary computed tomography, perfusion 
imaging and coronary angiography, which may have effects on numbers diagnosed patients 
with CHD over time. The Emerging Risk Factor Collaboration (ERFC) study used definitions 
of nonfatal MI based on the World Health Organization criteria and of nonfatal stroke based 
on clinical and brain imaging features.17 In coding fatal outcomes, all contributing studies 
classified deaths according to the International Classification of Diseases. To facilitate head-
to-head comparisons, the study group recalibrated SCORE and RRS to the common CVD 
outcome employed by FRS and PCE. 
 
The main finding was that the performance of the original four risk algorithms varied 
substantially, predominantly due to differing extent of calibration.15 However, after re-
calibration, their performance was equalised. The authors found only minor differences 
among the algorithms in relation to risk discrimination based on the Harrell’s C-index, which 
is a measure of predictive accuracy that is not influenced by the extent of model calibration. 
Di Angelantonio and colleagues concluded that targeting of CVD preventive action to clinical 
practice would improve considerably due to higher accuracy of individual risk predictions.15 
One potential implication is that primary prevention guidelines should shift away from 
debates about the relative merits of certain risk algorithms and instead, achieve consensus 
about the need for more widespread use of any re-calibrated algorithm. 
 
To further evaluate the clinical usefulness of these available risk algorithms in the decision to 
initiate therapies such as lipid lowering drugs, the authors were able to estimate the number 
of individuals who would benefit from statin treatment. To conduct this analysis, certain 
assumptions were made: risk assessment for a population of aged ≥40 years without CVD 
and not already taking statins or meeting recommendations for statin treatment; including the 
same age structure of a standard population of the United States; age- and sex specific 
incidence rates for CVD events as in the current study; and statin use allocation according to 
the predicted 10-year CVD risk threshold by ACC/AHA guideline for first-onset fatal and non-
fatal CVD events (i.e., ≥7.5%), or by the ESC Guidelines for fatal CVD (i.e., ≥5%), with risk 
reduction of 20% with statin treatment in primary prevention. Based on re-calibration, it 
seemed that the proportion of individuals classified as high-risk reduced from 40% to 23%, 
and the number of individuals needed to initiate statin therapy to prevent one event reduced 
from 44-51 to around 38. This indicates an average improvement that could be achieved by 
re-calibration across a set of different populations.15 
 
The illustrations of the paper (e.g. Figure 4) clearly demonstrate the number of people 
classified as high-risk groups when using the specific risk scores and the substantial change 
after re-calibration calculations.15 It is not encouraging for clinicians if they are unable to rely 
on CVD scores in the decision to initiate drug therapy, of course, in addition to prescribing 
well documented life-style interventions such as physical exercise and healthy diet. To 
facilitate better clinical decision making, risk predictions need to be improved and 
appropriate population-wide thresholds should be set. Without accurate individual risk 
predictions, clinicians should not readily prescribe medications that could potentially be 
harmful. This relates especially for primary prevention as compared to drug initiation in 
secondary prevention populations in high-risk groups i.e. after the first non-fatal CVD event 
among patients with underlying atherosclerosis with evidence of the effects of drugs. As the 
number needed to treat is quite high in primary prevention populations, it may not be 
acceptable to initiate therapy that has the potential to cause harm. Regarding assessments 
of medication use; though a limitation, the authors clearly acknowledged that it was not 
possible to formally incorporate the impact of the potential hazards of the use of drugs in all 
included population studies. Second, information on medication use (lipid lowering, 
antihypertensive or antithrombotic drugs), including widely used invasive interventions such 
as percutaneous coronary intervention and coronary artery bypass surgery with active 
cardiovascular rehabilitation, which may have influenced long-term estimates of the 
observed CVD risk, could not be taken into account. 
 
Prevention with treatment of common risk factors, such as the North Karelia Project in 
Finland, has been a successful story in cardiology in many Western countries. Effective 
prevention has moved the age of first evidence of CHD from the younger to the elderly 
populace; meaning that more people are capable of continuing their active working lives 
independently of healthcare systems for longer periods without limitations due to CVDs. On 
the other hand, the form of CHD may have changed in recent times, patients being treated in 
the cardiology clinic, are older with co-morbidities compared to decades ago. 
 
This study’s main message on the importance of recalibration of risk scores is timely and 
relevant for advanced CVD prevention. The authors reported findings on the extent of CVD 
risk prediction improvement using re-calibration. We appreciate and applaud their efforts on 
pooling prospective studies on CVD risk factors together which extend further evidence on 
the clinical usefulness of risk scores. The study findings provide robust evidence on the 
implementation of risk scores helping to tailor therapy in modern CVD treatment; it is highly 
unlikely there is corresponding data from randomised studies which suggest the 
implementation of CVD risk assessment can translate into CVD prevention strategies using 
life-style interventions and drugs. Indeed, these study findings suggest that the use of well 
re-calibrated risk algorithms in clinical practice could improve targeted CVD prevention on a 
global scale. 
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 Table. Cardiovascular risk scores, their risk factors and outcomes in original studies 
Score Included risk factors Baseline 
age 
(range) 
Origin Baseline data 
collected (year (s)) 
Main outcome 
SCORE Age, smoking status, 
total cholesterol, HDL 
cholesterol systolic BP 
40-65 Europe 1967-1991 Fatal non-CHD CVD; 
fatal CHD 
PCE Age, smoking status, 
total cholesterol, HDL-
cholesterol, systolic 
BP, diabetes status 
40-79 USA 1987-1989; 1990-
1992; 1993-1995 / 
1989-1999 / 1985-
1986 / 
1968-1971; 1971-
1975; 1984-1987 
Non-fatal and fatal CHD 
or stroke 
FRS Age, smoking status, 
total cholesterol, HDL-
cholesterol, systolic 
BP, diabetes status 
30-74 USA 1968-1971; 1971-
1975; 1984-1987 
Fatal and non-fatal 
coronary and stroke 
events  
RRS Age, smoking status, 
total cholesterol, HDL-
cholesterol, systolic 
BP, hsCRP, HbA1c (if 
diabetic), parental 
history of MI<60 years 
Women: ≥ 
45 
 
Men: ≥ 50 
USA Women: 1992 
 
 
Men: 1995 
MI, ishemic stroke, 
coronary 
revascularization or 
CVD death 
BP = blood pressure; CHD = coronary heart disease; CVD = cardiovascular disease; FRS= Framingham Risk 
Score; HDL = high density lipoprotein; hsCRP = high sensitivity C-reactive protein; MI = myocardial infarction; 
PCE = Pooled Cohort Equations; RRS= Reynolds Risk Score; SCORE= Systematic Coronary Risk Evaluation 
 
 
